BCAX vs. MOR, TWST, VCEL, CPRX, MLTX, MRUS, BEAM, IBRX, ARWR, and HCM
Should you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include MorphoSys (MOR), Twist Bioscience (TWST), Vericel (VCEL), Catalyst Pharmaceuticals (CPRX), MoonLake Immunotherapeutics (MLTX), Merus (MRUS), Beam Therapeutics (BEAM), ImmunityBio (IBRX), Arrowhead Pharmaceuticals (ARWR), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.
Bicara Therapeutics vs.
Bicara Therapeutics (NASDAQ:BCAX) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking and earnings.
Bicara Therapeutics has higher earnings, but lower revenue than MorphoSys.
Bicara Therapeutics presently has a consensus target price of $41.20, indicating a potential upside of 216.92%. MorphoSys has a consensus target price of $18.25, indicating a potential downside of 3.74%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than MorphoSys.
Bicara Therapeutics has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Bicara Therapeutics' return on equity of 0.00% beat MorphoSys' return on equity.
18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Bicara Therapeutics had 3 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Bicara Therapeutics and 0 mentions for MorphoSys. Bicara Therapeutics' average media sentiment score of 0.58 beat MorphoSys' score of 0.00 indicating that Bicara Therapeutics is being referred to more favorably in the media.
MorphoSys received 14 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Bicara Therapeutics an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.
Summary
Bicara Therapeutics beats MorphoSys on 10 of the 14 factors compared between the two stocks.
Get Bicara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bicara Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BCAX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free BCAX Stock Alerts